Drug
Revefenacin
Revefenacin is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_4
2
50%
Ph phase_3
2
50%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (50.0%)
Phase 42 (50.0%)
Trials by Status
not_yet_recruiting125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_4
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
NCT07721922
completedphase_4
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
NCT05165485
completedphase_3
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
NCT03573817
completedphase_3
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
NCT03095456
Clinical Trials (4)
Showing 4 of 4 trials
NCT07721922Phase 4
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)
NCT05165485Phase 4
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
NCT03573817Phase 3
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
NCT03095456Phase 3
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4